1
|
Costa D, Nomdedeu M, Pereira A, Calvo X, Colomer J, Soler F, Luno E, Cervera J, Arnan M, Ramos F, Oiartzabal I, Arrizabalaga B, Tormo M, Diez-campelo M, Ortega M, Collado R, Granada I, Sanz G, Campo E, Esteve J. Clinical and Biological Significance of Y Chromosome Loss in a Series of 2,423 Male Patients with MDS and CMML. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30321-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
2
|
Calvo X, Arenillas L, Luño E, Senent L, Arnan M, Ramos F, Pedro C, Tormo M, Montoro J, Diez-Campelo M, Blanco M, Arrizabalaga B, Xicoy B, Bonanad S, Jerez A, Nomdedeu M, Ferrer A, Sanz G, Florensa L. Calculating IPSS-R by Enumerating Bone Marrow Blasts from Nonerythroid Cellularity Improves Outcome Prediction in MDS with Erythroid Predominance. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30351-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
3
|
Nomdedeu M, Tuechler H, Kuendgen A, Solé F, Schanz J, Hildebrandt B, Grau J, Pereira A, García-Manero G, Sekeres M, Komrokji R, Voso M, List A, Cazzola M, Sill H, Stauder R, Greenberg P, Germing U, Sanz G, Haase D. Chromosomal Aberrations in Therapy-Related Myelodysplastic Syndromes – Relations to Primary Disease, Therapy and Prognostic Significance. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30161-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
4
|
Guijo AR, Sánchez-Barba M, Santillana GS, Bernal T, Sangerman MA, Ortega FR, Olivé CP, Lozano MA, Betes VM, Valcárcel D, Ardanaz M, Brunet S, Lleonart JB, Tormo M, Xicoy B, Nomdedeu M, Cadenas FL, Berrocal JC, Cañizo M, Díez-Campelo M. What is the Outcome of Patients in the Intermediate IPSS-R Score Group? Spanish Approach for Better Stratification with Classical Tools. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30374-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
5
|
Etxabe A, Lara-Castillo MC, Cornet-Masana JM, Banús-Mulet A, Nomdedeu M, Torrente MA, Pratcorona M, Díaz-Beyá M, Esteve J, Risueño RM. Inhibition of serotonin receptor type 1 in acute myeloid leukemia impairs leukemia stem cell functionality: a promising novel therapeutic target. Leukemia 2017; 31:2288-2302. [DOI: 10.1038/leu.2017.52] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2016] [Revised: 01/12/2017] [Accepted: 02/06/2017] [Indexed: 12/25/2022]
|
6
|
Díaz-Beyá M, Brunet S, Nomdedéu J, Cordeiro A, Tormo M, Escoda L, Ribera JM, Arnan M, Heras I, Gallardo D, Bargay J, Queipo de Llano MP, Salamero O, Martí JM, Sampol A, Pedro C, Hoyos M, Pratcorona M, Castellano JJ, Nomdedeu M, Risueño RM, Sierra J, Monzó M, Navarro A, Esteve J. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia. Blood Cancer J 2015; 5:e352. [PMID: 26430723 PMCID: PMC4635188 DOI: 10.1038/bcj.2015.76] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2015] [Accepted: 08/03/2015] [Indexed: 12/14/2022] Open
Abstract
Acute myeloid leukemia (AML) is a heterogeneous disease whose prognosis is mainly related to the biological risk conferred by cytogenetics and molecular profiling. In elderly patients (⩾60 years) with normal karyotype AML miR-3151 have been identified as a prognostic factor. However, miR-3151 prognostic value has not been examined in younger AML patients. In the present work, we have studied miR-3151 alone and in combination with BAALC, its host gene, in a cohort of 181 younger intermediate-risk AML (IR-AML) patients. Patients with higher expression of miR-3151 had shorter overall survival (P=0.0025), shorter leukemia-free survival (P=0.026) and higher cumulative incidence of relapse (P=0.082). Moreover, in the multivariate analysis miR-3151 emerged as independent prognostic marker in both the overall series and within the unfavorable molecular prognostic category. Interestingly, the combined determination of both miR-3151 and BAALC improved this prognostic stratification, with patients with low levels of both parameters showing a better outcome compared with those patients harboring increased levels of one or both markers (P=0.003). In addition, we studied the microRNA expression profile associated with miR-3151 identifying a six-microRNA signature. In conclusion, the analysis of miR-3151 and BAALC expression may well contribute to an improved prognostic stratification of younger patients with IR-AML.
Collapse
Affiliation(s)
- M Díaz-Beyá
- Hematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain.,Josep Carreras Leukaemia Research Institute, Barcelona, Spain
| | - S Brunet
- Josep Carreras Leukaemia Research Institute, Barcelona, Spain.,Hematology Department and Biological Hematology Laboratory, Hospital de Sant Pau, Barcelona, IIB-Sant Pau Research Institute, Universitat Autonoma of Barcelona, Barcelona, Spain
| | - J Nomdedéu
- Josep Carreras Leukaemia Research Institute, Barcelona, Spain.,Hematology Department and Biological Hematology Laboratory, Hospital de Sant Pau, Barcelona, IIB-Sant Pau Research Institute, Universitat Autonoma of Barcelona, Barcelona, Spain
| | - A Cordeiro
- Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, Barcelona, Spain
| | - M Tormo
- Hematology Department, Hospital Clínico, Valencia, Spain
| | - L Escoda
- Hematology Department, Hospital Joan XXIII, Tarragona, Spain
| | - J M Ribera
- Josep Carreras Leukaemia Research Institute, Barcelona, Spain.,Hematology Department, Institut Català d'Oncologia (ICO)-Hospital Germans Trias i Pujol, Badalona, Spain
| | - M Arnan
- ICO, Hematology Department, Hospital Duran i Reynals, l'Hospitalet de Llobregat, Barcelona, Spain
| | - I Heras
- Hematology Department, Hospital Morales Meseguer, Murcia, Spain
| | - D Gallardo
- Hematology Department, ICO Josep Trueta, Girona, Spain
| | - J Bargay
- Hematology Department, Hospital de Son Llàtzer, Palma de Mallorca Hematology, Palma de Mallorca, Spain
| | | | - O Salamero
- Hematology Department, Hospital Vall d'Hebron, Barcelona, Spain
| | - J M Martí
- Hematology Department, Hospital Mutua de Terrassa, Barcelona, Spain
| | - A Sampol
- Hematology Department, Hospital de Son Llàtzer, Palma of Mallorca, Spain
| | - C Pedro
- Hematology Department, Hospital de Mar, Barcelona, Spain
| | - M Hoyos
- Hematology Department and Biological Hematology Laboratory, Hospital de Sant Pau, Barcelona, IIB-Sant Pau Research Institute, Universitat Autonoma of Barcelona, Barcelona, Spain
| | - M Pratcorona
- Hematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain.,Josep Carreras Leukaemia Research Institute, Barcelona, Spain
| | - J J Castellano
- Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, Barcelona, Spain
| | - M Nomdedeu
- Hematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain.,Josep Carreras Leukaemia Research Institute, Barcelona, Spain
| | - R M Risueño
- Josep Carreras Leukaemia Research Institute, Barcelona, Spain
| | - J Sierra
- Josep Carreras Leukaemia Research Institute, Barcelona, Spain.,Hematology Department and Biological Hematology Laboratory, Hospital de Sant Pau, Barcelona, IIB-Sant Pau Research Institute, Universitat Autonoma of Barcelona, Barcelona, Spain
| | - M Monzó
- Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, Barcelona, Spain
| | - A Navarro
- Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, Barcelona, Spain
| | - J Esteve
- Hematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain.,Josep Carreras Leukaemia Research Institute, Barcelona, Spain.,University of Barcelona, Barcelona, Spain
| |
Collapse
|
7
|
Bonanad S, De la Rubia J, Gironella M, Pérez Persona E, González B, Fernández Lago C, Arnan M, Zudaire M, Hernández Rivas JA, Soler A, Marrero C, Olivier C, Altés A, Valcárcel D, Hernández MT, Oiartzabal I, Fernández Ordoño R, Arnao M, Esquerra A, Sarrá J, González-Barca E, González J, Calvo X, Nomdedeu M, García Guiñón A, Ramírez Payer A, Casado A, López S, Durán M, Marcos M, Cruz-Jentoft AJ. Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale. J Geriatr Oncol 2015; 6:353-61. [PMID: 26139300 DOI: 10.1016/j.jgo.2015.03.003] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2014] [Revised: 03/24/2015] [Accepted: 03/31/2015] [Indexed: 12/27/2022]
Abstract
OBJECTIVES The purpose of this study was to develop a new brief, comprehensive geriatric assessment scale for older patients diagnosed with different hematological malignancies, the Geriatric Assessment in Hematology (GAH scale), and to determine its psychometric properties. MATERIALS AND METHODS The 30-item GAH scale was designed through a multi-step process to cover 8 relevant dimensions. This is an observational study conducted in 363 patients aged≥65years, newly diagnosed with different hematological malignancies (myelodysplasic syndrome/acute myeloblastic leukemia, multiple myeloma, or chronic lymphocytic leukemia), and treatment-naïve. The scale psychometric validation process included the analyses of feasibility, floor and ceiling effect, validity and reliability criteria. RESULTS Mean time taken to complete the GAH scale was 11.9±4.7min that improved through a learning-curve effect. Almost 90% of patients completed all items, and no floor or ceiling effects were identified. Criterion validity was supported by reasonable correlations between the GAH scale dimensions and three contrast variables (global health visual analogue scale, ECOG and Karnofsky), except for comorbidities. Factor analysis (supported by the scree plot) revealed nine factors that explained almost 60% of the total variance. Moderate internal consistency reliability was found (Cronbach's α: 0.610), and test-retest was excellent (ICC coefficients, 0.695-0.928). CONCLUSION Our study suggests that the GAH scale is a valid, internally reliable and a consistent tool to assess health status in older patients with different hematological malignancies. Future large studies should confirm whether the GAH scale may be a tool to improve clinical decision-making in older patients with hematological malignancies.
Collapse
Affiliation(s)
- S Bonanad
- Hematology Department, H. U. La Fe, Av. Fernando Abril Martorell, 106, 46026 Valencia, Spain.
| | - J De la Rubia
- Hematology Department, H. U. La Fe, Av. Fernando Abril Martorell, 106, 46026 Valencia, Spain
| | - M Gironella
- Hematology Department, H. U. Vall d'Hebrón, Passeig de la Vall d'Hebron, 119-129, 08035 Barcelona, Spain
| | - E Pérez Persona
- Hematology Department, H. U. Txagorritxu, c/ Jose Atxotegi, s/n, 01009 Vitoria-Gasteiz, Álava, Spain
| | - B González
- Hematology Department, H. U. de Canarias, Ctra. Ofra, s/n, 38320 San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain
| | - C Fernández Lago
- Hematology Department, C.H.U. A Coruña, As Xubias, 84, 15006, A Coruña, Spain
| | - M Arnan
- Hematology Department, Catalan Institute of Oncology, IDIBELL, Hospital Duran i Reynals, Avinguda Granvia de l'Hospitalet, 199-203 08908 l'Hospitalet de Llobregat, Barcelona, Spain
| | - M Zudaire
- Hematology Department, C.H. de Navarra, Av. Pío XII, 36, 31008 Pamplona, Navarra, Spain
| | - J A Hernández Rivas
- Hematology Department, H.U. Infanta Leonor, Avenida Gran Vía del Este, 80, 28031 Madrid, Spain
| | - A Soler
- Hematology Department, C.S. Parc Taulí, Parc Taulí, 1, 08208 Sabadell, Barcelona, Spain
| | - C Marrero
- Hematology Department, H. Ntra. Sra. de La Candelaria, Carretera del Rosario, 145, 38010 Santa Cruz de Tenerife, Spain
| | - C Olivier
- Hematology Department, C.H. de Segovia, c/ de Miguel Servet, s/n, Segovia, Spain
| | - A Altés
- Hematology Department, H. Sant Joan de Déu, Passeig de Sant Joan de Déu, 2, 08950 Esplugues de Llobregat, Barcelona, Spain
| | - D Valcárcel
- Hematology Department, H. U. Vall d'Hebrón, Passeig de la Vall d'Hebron, 119-129, 08035 Barcelona, Spain
| | - M T Hernández
- Hematology Department, H. U. de Canarias, Ctra. Ofra, s/n, 38320 San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain
| | - I Oiartzabal
- Hematology Department, H. U. Txagorritxu, c/ Jose Atxotegi, s/n, 01009 Vitoria-Gasteiz, Álava, Spain
| | - R Fernández Ordoño
- Hematology Department, H.U. Infanta Leonor, Avenida Gran Vía del Este, 80, 28031 Madrid, Spain
| | - M Arnao
- Hematology Department, H.U. de La Ribera, Carretera Corbera, km 1, 46600 Alzira, Valencia, Spain
| | - A Esquerra
- Hematology Department, C.S. Parc Taulí, Parc Taulí, 1, 08208 Sabadell, Barcelona, Spain
| | - J Sarrá
- Hematology Department, Catalan Institute of Oncology, IDIBELL, Hospital Duran i Reynals, Avinguda Granvia de l'Hospitalet, 199-203 08908 l'Hospitalet de Llobregat, Barcelona, Spain
| | - E González-Barca
- Hematology Department, Catalan Institute of Oncology, IDIBELL, Hospital Duran i Reynals, Avinguda Granvia de l'Hospitalet, 199-203 08908 l'Hospitalet de Llobregat, Barcelona, Spain
| | - J González
- Hematology Department, H.U. Virgen del Rocío, Avenida Manuel Siurot, s/n, 41013 Sevilla, Spain
| | - X Calvo
- Hematology Department, Hospital Clínic de Barcelona, Carrer Villarroel, 170, 08036 Barcelona, Spain
| | - M Nomdedeu
- Hematology Department, Hospital Clínic de Barcelona, Carrer Villarroel, 170, 08036 Barcelona, Spain
| | - A García Guiñón
- Hematology Department, H.U. Arnau de Vilanova, Avenida Alcalde Rovira Roure, 80, 25198 Lleida, Spain
| | - A Ramírez Payer
- Hematology Department, H.U. Central de Asturias, Calle Carretera de Rubín, s/n, 33011 Oviedo, Spain
| | - A Casado
- U. Autónoma de Madrid, Dynamic Science S.L., c/Azcona, 31, 28028 Madrid, Spain
| | - S López
- Celgene S.L.U., Paseo de Recoletos, 37, 28004 Madrid, Spain
| | - M Durán
- Celgene S.L.U., Paseo de Recoletos, 37, 28004 Madrid, Spain
| | - M Marcos
- Celgene S.L.U., Paseo de Recoletos, 37, 28004 Madrid, Spain
| | - A J Cruz-Jentoft
- Geriatric Department, H.U. Ramón y Cajal, Ctra. de Colmenar Viejo, km. 9,100, 28034 Madrid, Spain
| | | |
Collapse
|
8
|
Bargay J, Xicoy B, Brunet S, Tormo M, Pedro C, Coll R, Talarn C, Marti J, Nomdedeu M, Font X, Sampol A, Borrás J, Valcárcel D, Ribera J, Sierra J. 90 INTENSIVE CHEMOTHERAPY VERSUS NO INTENSIVE TREATMENT IN HIGH RISK MYELODYSPLASTYC SYNDROME (MDS) NO-HSCT CANDIDATES. Leuk Res 2015. [DOI: 10.1016/s0145-2126(15)30091-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
9
|
Mallolas J, Sarasa M, Nomdedeu M, Soriano A, López-Púa Y, Blanco JL, Martínez E, Gatell JM. Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients. HIV Med 2007; 8:131-4. [PMID: 17352770 DOI: 10.1111/j.1468-1293.2007.00442.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND Tuberculosis (TB) is a common opportunistic infection among HIV-infected people, and rifampicin is an important drug for the treatment of TB. However, administration of rifampicin in combination with antiretroviral therapy, particularly protease inhibitors, is difficult because of drug-drug interactions. METHODS We have performed a prospective study in three HIV-infected patients with TB treated with a rifampicin-containing regimen (rifampicin 600 mg per day) and antiretroviral therapy including only nucleoside reverse transcriptase inhibitors (NRTIs) plus atazanavir 300 mg once a day (qd) and ritonavir 100 mg qd, to evaluate whether the inducing effect of rifampicin on the drug-metabolizing enzyme cytochrome P450 (CYP) 3A4 could be overcome by the inhibitory effect of ritonavir. A complete pharmacokinetic evaluation of the steady-state concentrations of atazanavir and ritonavir was performed. RESULTS In all three cases, more than 50% of the time the atazanavir level was below the minimum recommended trough plasma level (150 ng/mL according to current pharmacokinetic guidelines) to inhibit HIV wild-type replication. CONCLUSION These results strongly indicate that the administration of rifampicin with a combination of atazanavir 300 mg qd plus ritonavir 100 mg qd must be avoided because subtherapeutic concentrations of atazanavir are produced.
Collapse
Affiliation(s)
- J Mallolas
- Infectious Diseases, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
| | | | | | | | | | | | | | | |
Collapse
|
10
|
González M, de Pablo J, Fuente E, Valdés M, Peri JM, Nomdedeu M, Matrai S. Instrument for Detection of Delirium in General Hospitals: Adaptation of the Confusion Assessment Method. Psychosomatics 2004; 45:426-31. [PMID: 15345788 DOI: 10.1176/appi.psy.45.5.426] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Delirium is a common and severe disorder that is often misdiagnosed. The use of screening instruments is advisable for its early detection and treatment. In this study, the authors present an adaptation of the Confusion Assessment Method in order to improve its psychometric properties. One hundred fifty-three elderly inpatients were assessed in a four-phase procedure. Interrater reliability was high (kappa = 0.89). Sensitivity was 90%, and specificity was 100%; the value for negative predictive accuracy was 97%, and the value for positive predictive accuracy was 100%. The adaptation has convergent agreement with two other mental status tests, the Mini-Mental Status Examination and the Delirium Rating Scale. Our results suggest that the adaptation of the Confusion Assessment Method is sensitive, specific, reliable, and easy to use by clinicians.
Collapse
Affiliation(s)
- M González
- IDIBAPS Clinical Institute of Psychiatry and Psychology, Internal Medicine Department, Hospital Clinic, University of Barcelona, Spain
| | | | | | | | | | | | | |
Collapse
|
11
|
Di Marco O, Aello M, Nomdedeu M, Van Houtte S. Effect of maize crop maturity on silage chemical composition and digestibility (in vivo, in situ and in vitro). Anim Feed Sci Technol 2002. [DOI: 10.1016/s0377-8401(02)00077-9] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|